MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042)

NCT04129398 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Cytomegalovirus Infection
Cytomegalovirus Disease

Interventions

DRUG: Letermovir tablet
DRUG: Letermovir IV

Sponsor

Merck Sharp & Dohme LLC